EP410: Gut Microbiome with Prof Talley Part 1

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. EP410: Gut Microbiome with Prof Talley Part 1 Introduction Dr. Warrick Bishop, a cardiologist and CEO of the Healthy Heart Network, hosts this episode featuring Professor Nicholas Talley, a Distinguished Laureate Professor of Medicine at Newcastle University who is a gastroenterologist, epidemiologist, researcher, and author. The episode explores the gut microbiome—the trillions of organisms living in our digestive system—and its emerging role in affecting multiple aspects of human health and disease prevention. Key Takeaways: The gut microbiome consists of trillions of organisms and their associated genes that colonize our bodies at birth, primarily from our mothers and birth environment, with composition being influenced by delivery method (vaginal vs. cesarean section). Microbiome composition is shaped throughout life by diet, exercise, medications, and environmental factors, and these organisms release chemicals and metabolites that are absorbed by the body and affect functions beyond just the gut. Obesity is associated with reduced microbiome diversity, and while animal models show that manipulating the microbiome can lead to weight loss, this approach has not yet been successfully replicated in humans. The relationship between microbiome changes and disease follows a bidirectional "chicken and egg" pattern—body changes can alter organisms, and organism changes can affect the body, making causation difficult to establish. Fecal microbial transfer (FMT) and prebiotics/probiotics are being tested as therapeutic approaches, though most over-the-counter probiotics are ineffective; results vary significantly depending on which donor organisms are used. Irritable bowel syndrome (IBS) treatment with FMT has shown mixed results, with some studies demonstrating dramatic symptom improvement while others failed, highlighting the critical importance of identifying the right organisms. Early research on FMT for Parkinson's disease is promising, with some trials showing significant improvements in disease symptoms, suggesting neurodegenerative diseases may become treatable through microbiome-based therapies. Oral bacteria can migrate to other parts of the digestive system where they don't belong; research has identified streptococcus from the mouth in the small intestine of patients with functional dyspepsia, suggesting misplaced organisms may drive disease. The microbiome field is complex because millions of organisms interact with each other and the body simultaneously, making it difficult to isolate which specific organisms drive particular health outcomes. Within the next 50 years, microbiome research may lead to cures for many diseases by identifying and treating the specific organisms responsible for disease development.